Wall Street analysts forecast that Neuronetics Inc (NASDAQ:STIM) will post earnings per share of ($0.45) for the current quarter, Zacks reports. Two analysts have made estimates for Neuronetics’ earnings, with the highest EPS estimate coming in at ($0.42) and the lowest estimate coming in at ($0.48). Neuronetics posted earnings of ($0.35) per share during the same quarter last year, which suggests a negative year over year growth rate of 28.6%. The firm is scheduled to report its next earnings report on Tuesday, March 3rd.
According to Zacks, analysts expect that Neuronetics will report full year earnings of ($1.63) per share for the current year, with EPS estimates ranging from ($1.66) to ($1.59). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.61) per share, with EPS estimates ranging from ($1.75) to ($1.46). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Neuronetics.
Neuronetics (NASDAQ:STIM) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.04. The firm had revenue of $16.00 million for the quarter, compared to analyst estimates of $16.13 million. Neuronetics had a negative net margin of 45.35% and a negative return on equity of 42.24%.
Several equities research analysts recently weighed in on the stock. BTIG Research cut their price objective on shares of Neuronetics to $11.00 and set an “average” rating for the company in a research report on Wednesday, November 6th. Zacks Investment Research downgraded Neuronetics from a “buy” rating to a “hold” rating in a research note on Saturday. JMP Securities lowered their target price on Neuronetics from $40.00 to $12.00 and set a “market outperform” rating for the company in a research note on Wednesday, November 6th. Finally, ValuEngine downgraded Neuronetics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $14.19.
In other news, CEO Christopher Thatcher sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $10.74, for a total value of $214,800.00. Corporate insiders own 12.00% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in STIM. Tower Research Capital LLC TRC bought a new position in Neuronetics during the 3rd quarter valued at $57,000. Bank of New York Mellon Corp boosted its stake in Neuronetics by 4.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 31,506 shares of the company’s stock worth $394,000 after purchasing an additional 1,270 shares during the period. Morgan Stanley boosted its stake in Neuronetics by 5,765.4% in the 2nd quarter. Morgan Stanley now owns 110,681 shares of the company’s stock worth $1,385,000 after purchasing an additional 108,794 shares during the period. Northern Trust Corp boosted its stake in Neuronetics by 4.6% in the 2nd quarter. Northern Trust Corp now owns 133,618 shares of the company’s stock worth $1,671,000 after purchasing an additional 5,877 shares during the period. Finally, Wasatch Advisors Inc. boosted its stake in Neuronetics by 21.2% in the 2nd quarter. Wasatch Advisors Inc. now owns 380,398 shares of the company’s stock worth $4,759,000 after purchasing an additional 66,444 shares during the period. 79.97% of the stock is owned by institutional investors and hedge funds.
Shares of Neuronetics stock traded down $0.17 during trading on Monday, reaching $4.71. The company’s stock had a trading volume of 2,723 shares, compared to its average volume of 103,283. The business’s 50-day moving average price is $8.72 and its 200-day moving average price is $11.36. The firm has a market cap of $100.93 million, a PE ratio of -1.74 and a beta of 0.98. Neuronetics has a 52 week low of $4.81 and a 52 week high of $25.97. The company has a quick ratio of 5.95, a current ratio of 6.10 and a debt-to-equity ratio of 0.51.
Neuronetics Company Profile
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
See Also: What is a conference call?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.